Lymphoma Clinical Trials in Pessac
17 recruitingPessac, France
Showing 1–17 of 17 trials
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company65 enrolled82 locationsNCT07015242
Recruiting
Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche100 enrolled51 locationsNCT06806033
Recruiting
Phase 3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc.450 enrolled112 locationsNCT06765109
Recruiting
Phase 3
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Lymphoma
SecuraBio124 enrolled43 locationsNCT06522737
Recruiting
Phase 1Phase 2
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Peripheral T Cells Lymphoma (PTCL)
The Lymphoma Academic Research Organisation49 enrolled20 locationsNCT07018752
Recruiting
Glofitamab in Real Life
Large B-cell Lymphoma
The Lymphoma Academic Research Organisation250 enrolled30 locationsNCT06994169
Recruiting
Phase 2
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Non-hodgkin Lymphoma,B Cell
Ryvu Therapeutics SA178 enrolled36 locationsNCT06534437
Recruiting
Phase 2
Study of Lacutamab in Peripheral T-cell Lymphoma
Relapse/RecurrencePeripheral T Cell Lymphoma
The Lymphoma Academic Research Organisation56 enrolled64 locationsNCT04984837
Recruiting
Phase 1Phase 2
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
Peripheral T Cells Lymphoma (PTCL)
Xenothera SAS54 enrolled8 locationsNCT06495723
Recruiting
Phase 3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Follicular Lymphoma
The Lymphoma Academic Research Organisation790 enrolled49 locationsNCT06284122
Recruiting
Phase 2
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Refractory High Grade B-Cell LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma Refractory+1 more
The Lymphoma Academic Research Organisation65 enrolled13 locationsNCT06271057
Recruiting
Not Applicable
Transplantation After Complete Response In Patients With T-cell Lymphoma
Peripheral T Cell Lymphoma
Hospices Civils de Lyon204 enrolled48 locationsNCT05444712
Recruiting
Phase 2
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B Cell Lymphoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)102 enrolled50 locationsNCT04920617
Recruiting
Phase 2
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Chronic Lymphocytic LeukemiaHodgkin LymphomaMyeloma+4 more
University Hospital, Clermont-Ferrand150 enrolled20 locationsNCT04935684
Recruiting
REal World Data in LYmphoma and Survival in Adults
Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)+4 more
Hospices Civils de Lyon6,000 enrolled37 locationsNCT03869619